ArticleJournal of managed care & specialty pharmacy2017

Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.

Steven R Feldman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.